Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis
Keyword(s):
Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequently developed self-limited cytomegalovirus disease. Cytomegalovirus infection has been reported during treatment with natalizumab, and in this study, we use new techniques to analyze the possible association of cytomegalovirus infection with natalizumab.
2018 ◽
Vol 41
(6)
◽
pp. 199-201
◽
2010 ◽
Vol 17
(2)
◽
pp. 198-203
◽
2015 ◽
Vol 358
(1-2)
◽
pp. 201-206
◽
2012 ◽
Vol 78
(Meeting Abstracts 1)
◽
pp. P02.135-P02.135
2014 ◽
Vol 341
(1-2)
◽
pp. 22-27
◽
2016 ◽
Vol 10
◽
pp. 36-43
◽